AI and the Pharmaceutical Industry — 2026-11-14 (Sat)
This section covers corporate investment behaviour of pharmaceutical companies, not the efficacy or safety of any medicinal product. Headlines are quoted as published; no claim about product performance is made or implied by this site. Collection and classification are automated and may misclassify or miss items. Disclaimer
Harvested 452Accepted 3Stale 109Duplicate 49Low-quality source 36Market noise 10Market research 2Off-topic 224No investment signal 18
💰 Investment MapAmounts are extracted from source text by pattern matching only. No currency conversion.
| Amount | Deal | Function | Source |
|---|---|---|---|
| $33 million | Absci's third-quarter loss widens to $33 million as first proof-of-concept data for its AI-designed hair-loss drug arrive in December | 🏛️ Enterprise AI Platform & Governance | MLQ.ai |
| $2.2 Million | [Twist Bioscience Q4 2026 Earnings Call] Twist Bioscience Hits Positive Adjusted EBITDA of $2.2 Million as AI Drug Discovery Revenue Surges 175%, Guides FY2027 to $550–560 Million | 🧬 Drug Discovery | BigGo Finance |
🧬 Drug Discovery1
- S1 DeploymentAstellas Deploys Structure Prediction AI "Boltz-2 NIM" to Democratize and Accelerate Drug Discovery — NVIDIA11/14 02:05 JSTAstellas
🧪 Clinical Development0
No items today · See past 90 days →
📑 CTD / Regulatory Submission0
No items today · See past 90 days →
🩺 GCP Operations0
No items today · See past 90 days →
📘 ICH Guidelines & AI0
No items today · See past 90 days →
🛡️ Pharmacovigilance / GVP0
No items today · See past 90 days →
📊 RWE / Evidence Generation0
No items today · See past 90 days →
🎓 Medical Affairs0
No items today · See past 90 days →
💼 Sales0
No items today · See past 90 days →
📣 Marketing0
No items today · See past 90 days →
🚚 Distribution / Supply Chain0
No items today · See past 90 days →
✅ GQP / Quality Assurance0
No items today · See past 90 days →
👥 Human Resources0
No items today · See past 90 days →
💴 Finance & Accounting0
No items today · See past 90 days →
🏛️ Enterprise AI Platform & Governance2
- S4 Amount disclosedAbsci's third-quarter loss widens to $33 million as first proof-of-concept data for its AI-designed hair-loss drug arrive in December$33 million — MLQ.ai11/13 05:27 JSTAbsci
- S1 DeploymentSAP's AI Story Now Needs a Receipt: Store Test, Pharma Rollout and a January Deadline — ad-hoc-news.de11/13 14:40 JST